Literature DB >> 28699033

Low white blood cell count is independently associated with chronic kidney disease progression in the elderly: the CKD-ROUTE study.

Yohei Arai1, Eiichiro Kanda2,3, Soichiro Iimori1, Shotaro Naito1, Yumi Noda4, Sei Sasaki1, Eisei Sohara1, Tomokazu Okado1, Tatemitsu Rai1, Shinichi Uchida1.   

Abstract

BACKGROUND: Elevated white blood cell (WBC) count is a well-known predictor of chronic kidney disease (CKD) progression. However, elderly patients commonly fail to develop a high WBC count in response to several diseased states and may instead present a low WBC count. Therefore, we hypothesized that low WBC count, in addition to high WBC count, is associated with CKD progression in the elderly.
METHODS: We conducted a prospective cohort study using 3-year follow-up data from the CKD Research of Outcomes in Treatment and Epidemiology study. In the present study, participants aged over 60 years with pre-dialysis CKD stages G2-G5 were eligible. Patients were stratified into three groups according to WBC count using tertiles (T). The primary outcome was a composite of end-stage renal disease and a 50% reduction in estimated glomerular filtration rate. Data were analyzed using Cox proportional hazard models with adjustments for covariates.
RESULTS: We enrolled 697 patients (males, 69%). The median WBC count was 6100 cells/µl (T1, <5400, n =  222; T2, 5400-6900, n =  235; T3, ≥6900, n = 240). During a median follow-up of 868 days, the primary outcome was observed in 170 patients, whereas 54 patients died. T1 and T3 had significantly higher hazard ratios (HR) than T2 (T1, HR 1.69, 95% confidence interval 1.14-2.51; T3, HR 1.63, 95% confidence interval 1.10-2.41). Moreover, T1 had a significantly higher adjusted HR (1.54, 95% confidence interval 1.00-2.37).
CONCLUSION: Low WBC count is independently associated with CKD progression in the elderly.

Entities:  

Keywords:  Bone marrow dysfunction; Chronic kidney disease; End-stage renal disease; Inflammation; Malnutrition; White blood cell count

Mesh:

Year:  2017        PMID: 28699033     DOI: 10.1007/s10157-017-1441-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  35 in total

1.  NORMAL VARIATIONS WITH AGING OF THE AMOUNT OF HEMATOPOIETIC TISSUE IN BONE MARROW FROM THE ANTERIOR ILIAC CREST. A STUDY MADE FROM 177 CASES OF SUDDEN DEATH EXAMINED BY NECROPSY.

Authors:  R J HARTSOCK; E B SMITH; C S PETTY
Journal:  Am J Clin Pathol       Date:  1965-04       Impact factor: 2.493

2.  Relative lymphocyte count as a marker of progression of chronic kidney disease.

Authors:  So Mi Kim; Hyun Woo Kim
Journal:  Int Urol Nephrol       Date:  2014-03-18       Impact factor: 2.370

3.  Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis.

Authors:  Sungjin Chung; Ho Cheol Song; Seok Joon Shin; Sang-Hyun Ihm; Chan Seok Park; Hee-Yeol Kim; Chul Woo Yang; Yong-Soo Kim; Euy Jin Choi; Yong Kyun Kim
Journal:  Hemodial Int       Date:  2012-04       Impact factor: 1.812

4.  Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease.

Authors:  Arianne van Koppen; Jaap A Joles; Lennart G Bongartz; Jens van den Brandt; Holger M Reichardt; Roel Goldschmeding; Tri Q Nguyen; Marianne C Verhaar
Journal:  Cell Transplant       Date:  2012       Impact factor: 4.064

5.  The use of vitamin D analogs is independently associated with the favorable renal prognosis in chronic kidney disease stages 4-5: the CKD-ROUTE study.

Authors:  Yohei Arai; Eiichiro Kanda; Soichiro Iimori; Shotaro Naito; Yumi Noda; Tomoki Kawasaki; Hidehiko Sato; Ryoichi Ando; Sei Sasaki; Eisei Sohara; Tomokazu Okado; Tatemitsu Rai; Shinichi Uchida
Journal:  Clin Exp Nephrol       Date:  2016-06-25       Impact factor: 2.801

Review 6.  Aspects of immune dysfunction in end-stage renal disease.

Authors:  Sawako Kato; Michal Chmielewski; Hirokazu Honda; Roberto Pecoits-Filho; Seiichi Matsuo; Yukio Yuzawa; Anders Tranaeus; Peter Stenvinkel; Bengt Lindholm
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

Review 7.  Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.

Authors:  Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

8.  Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.

Authors:  Stephanie K Bunt; Ashley M Mohr; Jennifer M Bailey; Paul M Grandgenett; Michael A Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2012-08-05       Impact factor: 6.968

9.  Age-related decline in proliferative potential of purified stem cell candidates.

Authors:  P M Lansdorp; W Dragowska; T E Thomas; M T Little; H Mayani
Journal:  Blood Cells       Date:  1994

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more
  2 in total

1.  Baseline liver function tests and full blood count indices and their association with progression of chronic kidney disease and renal outcomes in Aboriginal and Torres Strait Islander people: the eGFR follow- up study.

Authors:  Sandawana William Majoni; Federica Barzi; Wendy Hoy; Richard J MacIsaac; Alan Cass; Louise Maple-Brown; Jaquelyne T Hughes
Journal:  BMC Nephrol       Date:  2020-12-01       Impact factor: 2.388

Review 2.  Blood and Salivary Inflammatory Biomarkers Profile in Patients with Chronic Kidney Disease and Periodontal Disease: A Systematic Review.

Authors:  Lisandra Taísa Reginaldo Tavares; Mariana Saavedra-Silva; Joaquín Francisco López-Marcos; Nélio Jorge Veiga; Rogerio de Moraes Castilho; Gustavo Vicentis de Oliveira Fernandes
Journal:  Diseases       Date:  2022-02-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.